No need to market the core assets when they have been sold off. IMO, Silenor has already been sold to GSK. GSK will take Silenor to over the counter status increasing potential revs to $100mil. That is why GSK was willing to renegotiate the debt for modest terms.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.